Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Group 1 - The core announcement involves China Resources Pharmaceutical (03320.HK) planning to establish a fund with an expected scale of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology [1] - The company intends to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager after its establishment [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 內幕消息 擬議成立基金暨關連交易 本公告乃由本公司根據上市規則第13.09(2)條及《證券及期貨條例》（香港法 例第571章）第XIVA部內幕消息條文作出。 華潤醫藥（汕頭）、華潤雙鶴、雙鶴（北京）、華潤醫藥投資（各自為本公司之附 屬公司）與漢威華酉汕頭及其他有意合夥人就成立預期規模為人民幣5億元 之基金進行協商。基金預期主要從事合成生物學、創新藥物及生物技術領域 的高增長企業投資。本集團擬承諾出資總額預期為不高於人民幣1.23億元， 約佔基金承諾出資總額的24.6%。預期基金於成立後將不會入賬為本公司之 附屬公司。預期深圳華潤資本將獲委託為基金之基金管理人。 1 於本公告之日，一名擬議合夥人漢威華酉汕頭為華潤投資（天津）的全資附 屬公司，而華潤投資（天津）由本公司控股股東華潤集團最終持有。因此，漢 威華酉汕頭構成了本公司的關連人士，而有限合夥協議 ...

格隆汇8月12日丨华润医药(03320.HK)公布，公司将于2025年8月26日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 華潤醫藥集團有限公司 主席 白曉松先生 中國，2025年8月12日 於本公告日期，董事會包括本公司主席及執行董事白曉松先生；本公司執行董事 陶然先生及鄧蓉女士；本公司非執行董事郭巍女士、孫永強先生、王宇航先生、 郭川先生及焦瑞芳女士；及本公司獨立非執行董事招敏慧女士、傅廷美先生、張 克堅先生及史錄文先生。 董事會會議日期 茲公告華潤醫藥集團有限公司（「本公司」）將於2025年8月26日（ 星期二 ）舉行本公 司董事（「董事」）會（「董事會」）會議，旨在（ 其中包括 ）考慮及通過（ 如適用 ）(i)本公 司及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈；以及(ii)宣派 中期股息（ 如有 ）。 承董事會命 （於香港註冊成立的有限公司） （股份代號：3320） ...

近年来，华润医药商业经营规模位居行业前列，营收和净利润有所增长，但毛利率有下降趋势。 根据2025年6月披露的"25润药05"公司债(第三期)募集说明书，2022—2024年度，华润医药商业实现营 业收入分别为1,828.87亿元、2,024.81亿元和2,132.00亿元；其中，公司医疗纯销业务收入分别为1,271.12 亿元、1,426.67亿元和1,481.96亿元，分别占营业收入的69.50%、70.46%和69.51%，为公司最主要的营 业收入来源。 财报数据显示，2022—2024年度，华润医药商业净利润分别为17.85亿元、19.68亿元及22.13亿元；同期 营业毛利率分别为6.88%、6.47%及6.51%。 据华润医药商业官网资料，这家总资产超过1500亿元的医药流通企业前身为北京医药股份有限公司， 2010年进入华润体系，由地区性公司发展成为全国性医药流通企业。2012年，公司更名为华润医药商业 集团有限公司，此后于2023混改引战成功，进入股权多元化新时期。 此次公司高层人事调整，由现任华润医药商业党委副书记、总经理郭霆代行财务负责人职责，公司公告 称将尽快安排聘任新任财务负责人。与此 ...

Group 1: Industry Overview - The Chinese pharmaceutical distribution market can be divided into three competitive tiers, with the first tier consisting of national wholesale giants such as China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong, all generating over 100 billion in revenue [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoyao Pharmacy and Yifeng Pharmacy, indicating significant changes in the top five rankings compared to the previous year [3] - The e-commerce segment is led by Ark Health's online pharmacy, which is pioneering a new H2H (Hospital To Home) smart healthcare model [4] Group 2: Strategic Analysis - The strategic cluster analysis of listed companies in the pharmaceutical distribution industry indicates that leaders such as China Resources Pharmaceutical, Shanghai Pharmaceuticals, Jiuzhoutong, and China National Pharmaceutical Group have revenues exceeding 100 billion and are well-established in the market [5] - The competitive landscape is characterized by intense competition, with numerous participants including wholesale and retail pharmaceutical companies, as well as brand operators entering the supply chain [7] Group 3: Competitive Forces - The analysis using Porter's Five Forces model reveals a highly competitive environment in the pharmaceutical distribution industry, with a quantification of competitive forces ranging from 0 (minimum) to 1 (maximum) [7]

Core Insights - The Chinese pharmaceutical distribution market is segmented into three competitive tiers, with major players like China National Pharmaceutical, Shanghai Pharmaceuticals, and China Resources Pharmaceutical leading the first tier with revenues exceeding 100 billion [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoda Pharmacy and Yifeng Pharmacy, indicating significant changes in the rankings from 2022-2023 [3][4] - In the e-commerce sector, Fangzhou Jianke leads the online pharmacy rankings, emphasizing the shift towards technology-driven healthcare solutions [5] Competitive Landscape - The pharmaceutical distribution industry is characterized by intense competition, with numerous participants including wholesale, retail, and brand operation companies, as well as e-commerce platforms entering the market [7] - The five forces analysis indicates a high threat from potential entrants and moderate bargaining power from downstream medical institutions and patients [7] - The strategic cluster analysis reveals that leading companies like China Resources Pharmaceutical and Shanghai Pharmaceuticals are positioned as market leaders due to their extensive experience and comprehensive business layouts [5][6] Retail Pharmacy Rankings - The top five retail pharmacies are Dazhenlin, Guoda Pharmacy, Yifeng Pharmacy, Laobaiyi, and Yixintang, reflecting a dynamic market with significant shifts in rankings [3][4] - Other notable pharmacies in the top 25 include Henan Zhang Zhongjing Pharmacy and Shandong Yanjitang, showcasing a diverse competitive landscape [3] E-commerce Pharmacy Rankings - Fangzhou Jianke leads the online pharmacy sector, followed by 1Yao.com and JD Health, highlighting the growing importance of digital platforms in the pharmaceutical distribution market [5] - The focus on technology and innovation is evident as companies aim to connect patients with medical services more effectively [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 2 頁 共 10 頁 v 1.1.1 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 華潤醫藥集團有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03320 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 6,282,510,461 | | 0 | | 6,282,510,461 | | ...